Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT. A week off post-vaccine: definitely worth considering in stable disease #ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD

• https://x.com/drdavidliew/status/1857803007662157981/photo/1

It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time. MarketScan data tell a story of fashion and fame. What will the next 20 years be like? #ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc

• https://x.com/drdavidliew/status/1857797170591912008/photo/1

Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N

• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1
• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1

#0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY

• https://x.com/CaoilfhionnMD/status/1857801047302930494/photo/1

EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

• https://x.com/Dr_Brian_MD/status/1857484737084047833/photo/1

Knee OA Krill oil - No benefit in randomized PBO control study MTX (25 mg) for pain - modest diff in pain (numerical, not WOMAC), lost by 12 mo STEP-9: GLP1 agonist for BMI>30 w knee OA. 60% better than PBO. Wt or other benefits? @RheumNow Michael Pillinger #ACR24 year in review https://t.co/dMw4T0tWLX

• https://x.com/ericdeinmd/status/1857770831306240202/photo/1
• https://x.com/ericdeinmd/status/1857770831306240202/photo/1
• https://x.com/ericdeinmd/status/1857770831306240202/photo/1

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

• https://x.com/Dr_Brian_MD/status/1857502436371607960/photo/1